Johnson & Johnson (NYSE: JNJ) on Monday, plunged -0.14% from the previous trading day, before settling in for the closing price of $155.01. Within the past 52 weeks, JNJ’s price has moved between $143.13 and $168.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 1.31% annually for the last half of the decade. The company achieved an average annual earnings per share of 0.33%. With a float of $2.40 billion, this company’s outstanding shares have now reached $2.41 billion.
In an organization with 131900 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 69.05%, operating margin of 25.22%, and the pretax margin is 20.1%.
Johnson & Johnson (JNJ) Insider Updates
Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Johnson & Johnson is 0.12%, while institutional ownership is 72.74%. The most recent insider transaction that took place on Aug 30 ’24, was worth 930,113. In this transaction VP Corporate Controller of this company sold 5,635 shares at a rate of $165.06, taking the stock ownership to the 18,973 shares. Before that another transaction happened on Aug 30 ’24, when Company’s Officer proposed sale 5,635 for $165.06, making the entire transaction worth $930,113.
Johnson & Johnson (JNJ) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 0.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.00% during the next five years compared to -0.27% drop over the previous five years of trading.
Johnson & Johnson (NYSE: JNJ) Trading Performance Indicators
Johnson & Johnson (JNJ) is currently performing well based on its current performance indicators. A quick ratio of 0.79 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.24. Likewise, its price to free cash flow for the trailing twelve months is 17.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.05, a number that is poised to hit 2.02 in the next quarter and is forecasted to reach 10.59 in one year’s time.
Technical Analysis of Johnson & Johnson (JNJ)
Let’s dig in a bit further. During the last 5-days, its volume was 6.94 million. That was inferior than the volume of 7.05 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 63.03%. Additionally, its Average True Range was 2.27.
During the past 100 days, Johnson & Johnson’s (JNJ) raw stochastic average was set at 29.68%, which indicates a significant decrease from 63.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 13.79% in the past 14 days, which was lower than the 15.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $159.13, while its 200-day Moving Average is $155.80. However, in the short run, Johnson & Johnson’s stock first resistance to watch stands at $155.22. Second resistance stands at $155.65. The third major resistance level sits at $156.30. If the price goes on to break the first support level at $154.15, it is likely to go to the next support level at $153.50. Assuming the price breaks the second support level, the third support level stands at $153.08.
Johnson & Johnson (NYSE: JNJ) Key Stats
Market capitalization of the company is 371.76 billion based on 2,407,623K outstanding shares. Right now, sales total 85,159 M and income totals 35,153 M. The company made 22,471 M in profit during its latest quarter, and 2,694 M in sales during its previous quarter.
